Tag Archives: BMY

Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)

Stocks discussed on the Lightning Round segment of Jim Cramer’s Mad Money Program, Tuesday, May 15.

Bullish Calls

Consolidated Edison (NYSE:ED): It’s a buy on weakness. Buy American Electric Power (NYSE:AEP) too as it’s a high quality utility.

Clorox (NYSE:CLX): Buy half now and the other half when it starts yielding 4%. It has growth possibilities.

....More>>>

Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)

Stocks discussed on the Lightning Round segment of Jim Cramer’s Mad Money Program, Tuesday, May 15.

Bullish Calls

Consolidated Edison (NYSE:ED): It’s a buy on weakness. Buy American Electric Power (NYSE:AEP) too as it’s a high quality utility.

Clorox (NYSE:CLX): Buy half now and the other half when it starts yielding 4%. It has growth possibilities.

....More>>>

Don’t Buy L Brands – Cramer’s Lightning Round (5/15/18)

Stocks discussed on the Lightning Round segment of Jim Cramer’s Mad Money Program, Tuesday, May 15.

Bullish Calls

Consolidated Edison (NYSE:ED): It’s a buy on weakness. Buy American Electric Power (NYSE:AEP) too as it’s a high quality utility.

Clorox (NYSE:CLX): Buy half now and the other half when it starts yielding 4%. It has growth possibilities.

....More>>>

Nektar Therapeutics: Substantial Unlocked Value In The NKTR-358 Franchise

In my whole life, I have known no wise people (over a broad subject matter area) who didn’t read all the time – none, zero. Youd be amazed at how much Warren reads – and at how much I read. My children laugh at me. They think Im a book with a couple of legs sticking out.

– Charlie Munger

Nektar Therapeutics (NASDAQ:NKTR) is one of the most robust growers....More>>>

Is Agenus Inc. (AGEN) a Buy?

Harnessing the power of the immune system to fight cancer is a big deal and Agenus Inc. (NASDAQ:AGEN) looks like a great way to follow the trend. This stock trades like a small-cap biotech, but a couple of candidates coming through its pipeline could help push annual revenue past the $1 billion mark. Plus, by this time next year, the company could have half a dozen or so new candidates in clinical....More>>>